Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UGCG | Q16739 | 7/20 | 0.60 |
| ▸ | SCN9A | Q15858 | 7/20 | 0.46 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.39 |
| ▸ | MET | P08581 | 1/20 | 0.39 |
| ▸ | AXL | P30530 | 1/20 | 0.39 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.39 |
| ▸ | MERTK | Q12866 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | AHR | P35869 | 1/20 | 0.39 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.38 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.38 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.38 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.38 |
| ▸ | F10 | P00742 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29907458 | 0.89 | UGCG (0.47) | UGCGSCN9AMETAXLTYRO3 | |
| SCHEMBL29907410 | 0.89 | UGCG (0.75) | UGCGSCN9AMETAXLTYRO3 | |
| SCHEMBL29907472 | 0.86 | UGCG (0.79) | UGCGSCN9AMETAXLTYRO3 | |
| SCHEMBL29907407 | 0.84 | UGCG (0.61) | UGCGSCN9AMETAXLTYRO3 | |
| SCHEMBL29907490 | 0.80 | UGCG (0.75) | UGCGSCN9AP2RY1 | |
| SCHEMBL29601829 | 0.78 | UGCG (0.59) | UGCGMETAXLTYRO3MERTK | |
| SCHEMBL29907661 | 0.76 | UGCG (0.47) | UGCGSCN9AMETAXLTYRO3 | |
| SCHEMBL29602191 | 0.76 | UGCG (0.46) | UGCGSCN9AMETAXLTYRO3 | |
| SCHEMBL29907372 | 0.76 | UGCG (0.63) | UGCGSCN9AMETAXLTYRO3 | |
| SCHEMBL29907426 | 0.75 | UGCG (1.00) | UGCGSCN9AMETAXLTYRO3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220289679-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220289679-A1 | HETEROCYCLIC COMPOUND | GBA1, GBA2, GALC | UGCG 10/4885SCN9A 1952/4885SCN5A 1023/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.